A Systematic Review of the Epidemiology and Disease Burden of Congenital and Immune-Mediated Thrombotic Thrombocytopenic Purpura

被引:3
作者
Du, Ping [1 ]
Cristarella, Tiffany [2 ]
Goyer, Camille [2 ]
Moride, Yola [2 ,3 ]
机构
[1] Takeda Dev Ctr Amer Inc, Global Evidence & Outcomes, Cambridge, MA 02142 USA
[2] YolaRX Consultants Inc, Montreal, PQ, Canada
[3] Rutgers State Univ, Ctr Pharmacoepidemiol & Treatment Sci, New Brunswick, NJ USA
来源
JOURNAL OF BLOOD MEDICINE | 2024年 / 15卷
关键词
thrombotic thrombocytopenic purpura; epidemiology; burden of illness; disease management; patient-reported outcomes; ADAMTS13; THERAPEUTIC PLASMA-EXCHANGE; FRENCH NATIONAL REGISTRY; SEVERE ADAMTS13 DEFICIENCY; SINGLE-CENTER EXPERIENCE; CLINICAL CHARACTERISTICS; HIGH PREVALENCE; ADULT PATIENTS; OUTCOMES; TTP; MANAGEMENT;
D O I
10.2147/JBM.S464365
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Congenital (cTTP) and immune-mediated (iTTP) thrombotic thrombocytopenic purpura are serious and rare clotting disorders resulting from a deficiency in the ADAMTS13 enzyme. A systematic review was conducted using the Ovid (R) MEDLINE & Embase databases to synthesize the epidemiology and burden of cTTP and iTTP worldwide (from January 1, 2010, to February 6, 2020, with an update that covered the period January 1, 2020-February 11, 2022). Outcomes of interest were incidence and prevalence of TTP, incidence of acute episodes, mortality, burden of illness (eg complications, healthcare utilization, patient-reported outcomes) and disease management. A total of 221 eligible observational studies were included. The incidence rate of acute episodes ranged from 0.19-0.35 person-years in adult patients with cTTP, and 1.81-3.93 per million persons per year for iTTP in the general population. Triggers of acute episodes were similar for cTTP and iTTP, with pregnancy and infection the most commonly observed. Exacerbation in patients with iTTP varied widely, ranging from 2.4-63.1%. All-cause mortality was observed in 0-13.4% of patients with cTTP, across studies and follow-up periods, and in 1.1% (median follow-up: 0.4 years) to 18.8% (1 year) of patients with iTTP during acute episodes. Cardiovascular, renal, and neurological disease were common complications. TTP also led to work disturbances, feelings of anxiety and depression, and general activity impairment. TTP treatment regimens used were generally reflective of current treatment guidelines. The evidence identified describes a high patient burden, highlighting the need for effective treatment regimens leading to improvements in outcomes. Considerable evidence gaps exist, particularly for disease epidemiology, patient-reported outcomes, costs of disease management, and associated healthcare resource utilization. This review may help increase disease awareness and highlights the need for additional real-world studies, particularly in geographical regions outside the United States and Western Europe.
引用
收藏
页码:363 / 386
页数:24
相关论文
共 50 条
  • [21] A case of "smoldering" immune-mediated thrombotic thrombocytopenic purpura manifesting as recurrent cardioembolic stroke
    Pepin, Mark E.
    Saca, Eyad
    Kwon, Soo Y.
    May, Jori
    CLINICAL CASE REPORTS, 2021, 9 (10):
  • [22] How I treat immune-mediated thrombotic thrombocytopenic purpura after hospital discharge
    Akwaa, Frank
    Antun, Ana
    Cataland, Spero R.
    BLOOD, 2022, 140 (05) : 438 - 444
  • [23] Diagnostic Challenges in a Case of Immune-Mediated Thrombotic Thrombocytopenic Purpura With Severe ADAMTS13 Deficiency
    Escoto-Pineda, Karel
    Alas-Pineda, Cesar
    Pavon-Varela, Dennis Javier
    Cortes, David
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (08)
  • [24] Congenital thrombotic thrombocytopenic purpura. Case report and review
    Nakastoev, I. M.
    Avdonin, P. P.
    Gribanova, E. O.
    Kalinin, N. N.
    Tsvetaeva, N., V
    Petrova, V., I
    Kalinina, I. I.
    Kanaeva, M. L.
    Zhuravlev, V. V.
    Biryukova, L. S.
    Avdonin, P., V
    Ryzhko, V. V.
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2018, 63 (02): : 191 - 199
  • [25] IMMUNE THROMBOCYTOPENIC PURPURA AND THROMBOTIC THROMBOCYTOPENIC PURPURA - DIAGNOSTIC DIFFICULTIES AND ERRORS
    Galstyan, G. M.
    Klebanova, E. E.
    Mamleeva, S. Yu
    Grzhimolovskii, A., V
    Kovrigina, A. M.
    Dvirnyk, V. N.
    Bessmertnyy, D. K.
    Fidarova, Z. T.
    Melikyan, A. L.
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2023, 68 (03): : 317 - 334
  • [26] Maternal and fetal outcomes of pregnancy occurring after a diagnosis of immune-mediated thrombotic thrombocytopenic purpura
    Brown, Jenna
    Potugari, Bindu
    Mazepa, Marshall A.
    Kohli, Ruhail
    Moliterno, Alison R.
    Brodsky, Robert A.
    Vaught, Jason A.
    Burwick, Richard
    Chaturvedi, Shruti
    ANNALS OF HEMATOLOGY, 2022, 101 (10) : 2159 - 2167
  • [27] Immunogenic hotspots in the spacer domain of ADAMTS13 in immune-mediated thrombotic thrombocytopenic purpura
    Velasquez Pereira, Leydi Carolina
    Roose, Elien
    Graca, Nuno A. G.
    Sinkovits, Gyorgy
    Kangro, Kadri
    Joly, Berangere S.
    Tellier, Edwige
    Kaplanski, Gilles
    Falter, Tanja
    Von Auer, Charis
    Rossmann, Heidi
    Feys, Hendrik B.
    Reti, Marienn
    Prohaszka, Zoltan
    Lammle, Bernhard
    Voorberg, Jan
    Coppo, Paul
    Veyradier, Agnes
    De Meyer, Simon F.
    Mannik, Andres
    Vanhoorelbeke, Karen
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2021, 19 (02) : 478 - 488
  • [28] Immune-Mediated Thrombotic Thrombocytopenic Purpura after BNT162b2 Vaccine
    Guney, Tekin
    Can, Ferda
    Akinci, Sema
    Kosemehmetoglu, Ozge Soyer
    Dilek, Imdat
    TURKISH JOURNAL OF HEMATOLOGY, 2022, 39 (01) : 74 - 75
  • [29] Comparison of Rituximab originator (MabThera) to biosimilar (Truxima) in patients with immune-mediated thrombotic thrombocytopenic purpura
    Stubbs, Matthew J.
    Low, Ryan
    McGuckin, Siobhan
    Newton, Rosalind
    Thomas, Mari
    Westwood, John P.
    Shah, Raakhee
    Cheesman, Simon
    Scully, Marie A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 (05) : 912 - 917
  • [30] ADAMTS13 conformation and immunoprofiles in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura
    Sakai, Kazuya
    Matsumoto, Masanori
    De Waele, Laure
    Dekimpe, Charlotte
    Hamada, Eriko
    Kubo, Masayuki
    Tersteeg, Claudia
    De Meyer, Simon F.
    Vanhoorelbeke, Karen
    BLOOD ADVANCES, 2023, 7 (01) : 131 - 140